Steve Lazar

Steve Lazar is a patent attorney with over 35 years’ experience in advising clients in the biotechnology, pharmaceutical, nutraceutical and chemical industries. Steve works with senior management teams to develop and implement strategies for protection of core intellectual property assets. He also conducts due diligence in connection with mergers and acquisitions involving extensive intellectual property positions; drafts and negotiates licensing agreements; and conducts patentability searches and freedom-to-operate analyses with respect to third party patent positions.

 Prior to consulting to industry, Steve served as Vice-President and Worldwide Head of Intellectual Property for GPC Biotech, Inc.  Prior to GPC, Steve held senior patent counsel positions with Genzyme and Genetics Institute/Wyeth Pharmaceuticals. Steve began his legal career with Fitzpatrick, Cella, Harper & Scinto in New York. Steve’s consulting clients have included GlycoFi, Inc. (acquired by Merck), Momenta Pharmaceuticals, Taligen Therapeutics (acquired by Alexion Pharmaceuticals), Bluebird Bio, KSQ Therapeutics, X4 Pharmaceuticals and Aveo Oncology.